BREAKING

Saturday, June 8, 2019

Liquid Biopsy Uses Blood Tests to Track and Treat Cancer



Wazzup Pilipinas!

MakatiMed discusses developing its own “homebrew” for monitoring cancer treatment

When a patient has a suspicious lump or shows cancer symptoms, one of the first things a doctor can perform is a tissue biopsy. This procedure collects cells for a closer examination to determine if cancer is indeed present, indicate what type it is, and provide clues on the course the disease is likely to take (prognosis) – which in turn, impacts the treatment the patient will receive.

Though remaining the gold standard in detecting and getting information on cancer, tissue biopsies can be risky, invasive, and painful. The inaccessibility of a tumor, as well as existing health conditions, often prevent some patients from undergoing the procedure. Still, there is no question about the importance of biopsies as these help guide doctors on personalized treatment strategies for their patients.

According to Makati Medical Center’s Jose Maria C. Avila, MD, co-director of the Center for Regenerative Medicine (CRM), the hospital has, in recent years, began offering liquid biopsy as a complementary procedure for monitoring and treating cancer patients.

“Because of how a tissue biopsy is conducted, repeatedly performing the procedure will be difficult for patients. But we still need to track tumors as they change and develop overtime to allow doctors to gauge a patient’s response to treatment and make necessary adjustments when needed.”

Liquid biopsy essentially uses blood from a patient to collect a sample of cancer cells or parts of DNA. “The procedure is less invasive since we are only drawing blood,” says Dr. Avila. “That’s easier on a patient since we have to perform the procedure a number of times to monitor their progress.”

Another benefit is being able to further personalize treatment. The procedure detects mutations from fragments collected in the blood, and a mutation of a tumor can vary greatly in the kind of treatment it requires.

As Dr. Avila explains, “This is personalized medicine. A tumor will have a mutation that is unique, and there’s a treatment needed for this particular mutation, and this individual cancer. A kind of treatment can work for one patient but not for another, and we want to be able to make the best decisions for each individual patient.”

Currently, MakatiMed utilizes liquid biopsy as a complementary procedure, and not as a replacement to tissue biopsy – at least not yet, as the approach is still evolving. “What we utilize it for right now is on the prognostic side, for monitoring patients’ response to treatment. Although, there are certain circumstances wherein liquid biopsy may be considered an option,” Dr. Avila points out.

These include if the patient cannot undergo tissue biopsy due to the location of the tumor or other factors affecting his or her health condition, or if the situation is critical and tissue biopsy will present complications in procuring samples as quickly as possible.

The CRM has also developed a “homebrew” liquid biopsy for its patients. “Our method detects gene expressions. Gene expressions determine what the cell can do and how it responds to its changing environment. There are a number of gene expressions that correspond to a certain type of cancer,” says Dr. Avila.

He continues, “After a patient is diagnosed with the specific type of cancer and receives the first or second round of treatment, we can use the liquid biopsy to monitor how the patient is responding by looking for these gene expressions. The oncologist can then adjust or change the treatment in order to decrease these expressions.”

As of now, the CRM is offering the liquid biopsy procedure for patients with lung cancer, prostate cancer, breast cancer, and soon, colon cancer. MakatiMed has also selected the U.S.-based specialty cancer diagnostics company Precipio, Inc. as its provider for the mutation enhancement technology used in liquid biopsies.

“With liquid biopsy as a viable, effective and less invasive monitoring procedure to help address the challenges of tissue biopsies, MakatiMed is able to consistently provide quality healthcare for our patients,” Dr. Avila concludes.

For more information, please contact MakatiMed On-Call at +632.8888 999, email mmc@makatimed.net.ph, or visit www.makatimed.net.ph.

Frontrow International Partners with the UP Fighting Maroons



Wazzup Pilipinas!

The University of the Philippines Fighting Maroons continued to get support for their University Athletics Association of the Philippines (UAAP) Season 82 campaign as FRONTROW International, a dynamic and rapidly-expanding direct selling company in the health, beauty, and wellness industry in the Philippines became their newest backer. UP alumni Raymond “RS” Francisco, FRONTROW president (seated, right) and Sam Verzosa, FRONTROW CEO (seated, second from right) officially inked the Memorandum of Agreement on Saturday, May 18, with nowheretogobutUP Foundation (NTGBUP), a volunteer group supporting UP’s varsity programs. NTGBUP President and UPMBT Team Manager Atty. Agaton Uvero (seated left), Maroons Head Coach Bo Perasol (seated, second from left), the coaching staff and the UP Fighting Maroons attended the signing ceremony at the Verzosa Residence in Quezon City. 

FDCP Hosts Its First Session of Film Dev’t Lab in Davao



Wazzup Pilipinas!

The Film Development Council of the Philippines (FDCP) continues its developmental programs for the empowerment of regional cinema with the first-ever Southern Voices Film Lab (SOVOLAB), which aims to advance and develop feature film projects from Mindanaoan filmmakers.

Seven (7) projects in script development from first, second, and third-time filmmakers from Mindanao have been selected for the SOVOLAB, including “Diwalwal” by Jarell Serencio, “Mga Yawa sa Paraiso” by Joe Bacus, “The Widow” by Ryanne Murcia, “Virgins of the River” by Julienne Joy Ilagan, “Cangrejos” by Zurich Chan, “Misery Mountain” by Orvil Bantayan, and “Dancing the Tide” by Xeph Suarez. These projects will undergo the first leg of the Lab from June 7 to 9, 2019 in Tagum City, Davao del Norte.

The first leg includes international mentors Raymond Phathanavirangoon, the Executive Director of the Southeast Asia Fiction Film Lab (SEAFIC) for producing, and Maggie Lee, the Chief Asia Film Critic for Variety for script development, as well as Bianca Balbuena, an award-winning producer for creative producing, and Mindanaoan filmmaker Sheron Dayoc.




FDCP Chairperson and CEO Mary Liza Diño expressed her excitement to meet new regional filmmakers and to help more unique tales from Mindanao come to life on the big screen. “As we celebrate the Sandaan, this is the perfect time to bring a film lab to the regions to let filmmakers from the South express their stories through films. We are looking forward to discovering more fresh voices from the regions through SOVOLAB.”

Through the labs, the selected filmmakers and producers will work with international and local mentors and consultants over the course of eight (8) months to refine their stories and to learn key industry practices to guide the production of their films. During the final session, the participants will be presenting a 7-minute pitch of their project to the jury. Two (2) projects will bring home the SOVOLAB co-production grant worth of One Million Pesos.
Ang Pambansang Blog ng Pilipinas Wazzup Pilipinas and the Umalohokans. Ang Pambansang Blog ng Pilipinas celebrating 10th year of online presence
 
Copyright © 2013 Wazzup Pilipinas News and Events
Design by FBTemplates | BTT